Requirement for CD28 may not be absolute for collagen-induced arthritis: Study with HLA-DQ8 transgenic mice

Journal of Immunology

Volumn 174, Issue 2, 2005, Pages 1118-1125

  Taneja, Veena ^a   Taneja, Neelam ^b   Behrens, Marshall ^a   Griffiths, Marie M ^c   Luthra, Harvinder S ^a   David, Chella S ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 2; CONCANAVALIN A; GAMMA INTERFERON; HLA DQ ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE SEVERITY; IMMUNIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

EID: 11844292035     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.2.1118     Document Type: Article

References (55)

1. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol, Today 15:321.
2. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
3. L. Immunity 3:87.
4. - T cells from rheumatoid arthritis patients. J. Immunol. 161:1018.
5. null T cells are associated with defects in apoptotic pathways. J. Immunol. 165:6301.
6. - T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J. Clin. Invest. 97:2027.
7. - costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 108:1185.
8. + T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Clin. Exp. Immunol. 106:218.
9. Groh, V., A. Bruhl, H. El-Gabalawy, J.L. Nelson, and T. Spies. 2003. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100:9452.
10. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA-4Ig. Science 265:1225.
11. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K.C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B-7-2 mAb treatment on the development of diabetes in the NOD mouse. J. Exp. Med. 181:1145.
12. Girvin, A. N., M. C. D. Canto, L. Rhee, B. Salomon, A. Sharpe, J. A. Bluestone, and S. D. Miller. 2000. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164:136.
13. Perrin, P. J., C. H. June, J. H. Maldonado, R. B. Ratts, and M. K. Racke. 1999. Blockade of CD28 during in vitro activation of encephlatogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 163:1704.
14. Gaglia, J. L., E. A.Greenfield, A. Mattoo, A. H. Sharpe, G. J. Freeman, and V. K. Kuchroo. 2000. Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J. Immunol. 165:6091.
15. Chitnis, T., N. Najafian, K. A. Abdallah, V. Dong, H. Yagita, M. H. Sayegh, and S. I. Khoury. 2001. CD28-independent induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 107:575.
16. Lenschow, D. J., K. C. Herold, L. Rhee, B. Patel, A. Koon, H. Y. Quinn, E. Fuchs. B. Singh, C. B. Thompson, and J. A. Bluestone. 1996. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285.
17. Bachmaier, K., C. Pummerer, A. Shahinian, J. Ionescu, N. Neu, T. W. Mak, and J. M. Peninger. 1996. Induction of autoimmunity in the absence of CD28 co-stimulation. J. Immunol. 157: 1752.
18. Girvin, A., M. C. Dal Canto, and S. D. Miller. 2000. CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J. Autoimmun. 18:83.
19. Mauri, C., C. Q. Chu, D. Woodrow, L. Mori, and M. Londei. 1997. Treatment of a newly established transgenic model of chronic arthritis with non depleting anti-CD4 monoclonal antibody. J. Immunol. 159:5032.
20. Doncarli, A., L. M. Stasiuk, C. Fournier, and O. Abehsira-Amar. 1997. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur. J. Immunol. 27:1451.
21. Tada, Y., K. Nagasawa, A. Ho, F. Morito, O. Ushiyama, N. Suzuki, H. Ohta, and T. W. Mak. 1999. CD28-deficient mice are highly resistant to collagen-induced arthritis. J. Immunol. 162: 203.
22. Webb, L. M. C., M. J. Walmsley, and M. Feldmann. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway requirement for both B7-1 and B7-2. Eur. J. Immunol. 26:2320.
23. Tellander, A. C., V. Pettersson, A. Runstrom, M. Anderson, and E. Michaelsson. 2001. Interference with CD28, CD80, CD86, or CD152 in collagen-induced arthritis. J. Autoimmn. 17:39.
24. Taneja, V., M. Griffiths, H. Luthra, and C. S. David. 1998. Modulation of HLA-DQ-restricted collagen-induced arthritis by HLA-DRB1 polymorphism. Int. Immunol. 10:1449.
25. Taneja, V., N. Taneja, T. Paisansinsup, M. Behrens, M. Griffiths, H. Luthra, and C. S. David. 2002. CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J. Immunol. 168:5867.
26. Nabozny, G. H., J. M. Baisch, S. Cheng, D. Cosgrove, M. M. Griffiths, H. S. Luthra, and C. S. David. 1996. HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. J. Exp. Med. 183:27.
27. Griffiths, M. M., E. J. Eichwald, J. H. Martin, C. B. Smith, and C. W. DeWitt. 1981. Immunogenetic control of experimental type II collagen induced arthritis. Arthritis Rheum. 24:781.
28. Wooley, P. H., H. S. Luthra, J. M. Stuart, and C. S. David. 1981. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 154:688.
29. Griffiths, M. M., G. H. Nabozny, J. Hanson, J. S. Harper, S. McCall, K. G. Moder, G. W. Cannon, H. S. Luthra, and C. S. David. 1994. Collagen induced arthritis and TCRs in SWR and B10.Q mice expressing EaK transgene. J. Immunol. 153:2758.
30. Krco, C. J., J. Pawelski, J. Harders, D. McCormick, M. Griffiths, H. S. Luthra, and C. S. David. 1996. Characterization of the antigenic structure of human type II collagen. J. Immunol. 156:2761.
31. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609.
32. Witherden, D. A., R. Boismenu, and W. L. Havran. 2000. CD81 and CD28 costimulate T cells through distinct pathways. J. Immunol. 165:1902.
33. + immunoregulatory T cells may not be involved in controlling autoimmune arthritis. Arthritis Res. Ther. 5:R106.
34. null T cells. J. Immunol. 168:3839.
35. Vacchio, M. S., and R. J. Hodes. 2003. CD28 costimulation is required for in vivo induction of peripheral tolerance in CD8 T cells. J. Exp. Med. 197:19.
36. Cannons, J. L., P. Lau, B. Ghumman, M. A. DeBenedette, H. Yagita, K. Okumura, and T. H. Watts. 2001. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167:1313.
37. - T cells in an autoimmune disease model. J. Clin. Invest. 112:1037.
38. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA Science 285:727.
39. Jamieson, A. M., A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle, and D. H. Raulet. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19.
40. Lee, I. F., H. Qin, J. Trudeau, J. Dutz, and R. Tan. 2004. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J. Immunol. 172:937.
41. Thorbecke, G. J., R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison, and M. A. Palladino. 1992. Involvement of endogenous tumor necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89:7375.
42. Johansson, A. C., A. S. Hansson, K. S. Nandakumar, J. Backlund, and R. Holmdahl. 2001. IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J. Immunol. 167:3505.
43. Rock, K. L., B. Benacerraf, and A. K. Abbas. 1984. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J. Exp. Med. 160:1102.
44. Cheon, H., S. J. Yu, D. H. Yoo, I. J. Chae, G. G. Song, and J. Sohn. 2002. Increased expression of pro-iflammatory cytokines and metalloproteinase-1 by TGF-β1 synovial fibroblasts from rheumatoid arthritis and normal individual. Clin. Exp. Immunol. 127:547.
45. Van Beuningen, H. M., H. L. Glansbeek, P. M. van der Kraan, and W. B. van der Berg. 2000. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-β injections. Osteoarthritis Cartilage 8:25.
46. Mori, M., S. C. Morris, T. Orekhova, M. Mariaosaria, G. Edward, and F. D. Finkelman. 2000. IL-4 promotes the migration of circulating B cells to the spleen and increases splenic B cell survival. J. Immunol. 164:5704.
47. Londei, M., C. M. Savill, A. Verhoef, F. Brennan, Z. A. Leech, V. Duance, R. N. Maini, and M. Feldmann. 1989. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 86:636.
48. Sekine, T., T. Kato, K. Masuko-Hongo, H. Nakamura, S. Yoshino, K. Nishioka, and K. Yamamoto. 1999. Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann. Rheum. Dis. 58:446.
49. He, X., A. Kang, and J. M. Stuart. 2000. Accumulation of T cells reactive to type II collagen in synovial fluid of patients with rheumatoid arthritis. J. Rheumatol. 27:589.
50. Pandiyan, P., D. Gartner, O. Soezeri, A. Radbruch, K. Schulze-Osthoff, and M. C. Brunner-Weinzierl. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. 199:831.
51. Kremer, J. M., R. Westhovens, M. Leon, E. DiGiorgio, R. Alten, S. Steinfeld, A. Russell, M. Dougados, P. Emery, I. F. Nuamah, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T cell activation with fusion protein CTLA-4Ig. N. Eng. J. Med. 13:1907.
52. Greenwald, R. J., V. A. Boussiotis, R. B. Lorsbach, A. K. Abbas, and A. H. Sharpe. 2001. CTLA-4 regulates induction of anergy in vivo. Immunity 14:145.
53. Egen, J. G., M. S. Kuhns, and J. P. Allison. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3:611.
54. 1 phase cell cycle check point. Immunity 8:57.
55. Catrina, A. I., A. K. Ulfgren, S. Lindblad, L. Grondal, and L. Klareskog. 2002. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann. Rheum. Dis. 61:934.